REal World Assessment for Patients Implanted With Implantable CardioverTer DefibrIllatOr Using Bluetooth Technology (REACTION)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Antonio Rapacciuolo, MD, PhD
- Phone Number: 081-7461111
- Email: antonio.rapacciuolo@unina.it
Study Locations
-
-
-
Naples, Italy, 80128
- Recruiting
- Prof Antonio Rapacciuolo,MD, PhD
-
Contact:
- Antonio Rapacciuolo
- Phone Number: +393470660290
- Email: antonio.rapacciuolo@unina.it
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- All patients implanted with an ICD as for standard indications
- Over 18 years of age
- Ability to provide informed consent for registry participation and be willing and able to comply with the protocol described evaluations
Exclusion Criteria:
- Subject who is, or is expected to be inaccessible for follow-up
- pregnancy
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
APP group
Patient wearing ICD with Bluetooth® technology and smartphone APP based remote monitoring
|
smartphone APP to monitor remotely patients implanted with ICD
|
|
Bedside transmitter group
Patient wearing ICD monitored remotely through a bedside transmitter
|
bedside transmitter to monitor remotely patients implanted with ICD
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Adherence
Time Frame: 12 months
|
The adherence will be measured through the following endpoints: • Compliance with RM quantified as percentage of patients who registered with the smartphone App |
12 months
|
|
Effectiveness
Time Frame: 12 months
|
The effectiveness based on the comparison between the App monitoring and the traditional remote control will be assessed through the following endpoints: • Percentage of time (days) with an active connection between device and the transmitter/smartphone app |
12 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Clinical benefits in CRT area:
Time Frame: 12 Months
|
Association between patient symptom-triggered transmissions and HF events or other clinical events detected by device diagnostics
|
12 Months
|
|
Clinical benefits in ICD therapies
Time Frame: 12 months
|
Clinical action taken as a result of appropriate or inappropriate ICD therapies
|
12 months
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ANTICIPATED)
Primary Completion
Study Completion (ANTICIPATED)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 137/21
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.